在胃食道癌中准HER2:对旧困境的新食欲
Antonella Cammarota1,2, Rachel Woodford1,3, Elizabeth C Smyth4
1Sarah Cannon Research Institute UK, 93 Harley St, London, UK.
胃食道癌症正在增加,HER2阳性病例受益于向治疗. 了解耐药机制是改善治疗策略和患者治疗结果的关键.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 胃肠病学 胃肠病学
背景情况:
- 与肥胖和逆流相关的胃食道癌症的发病率不断上升.
- 许多瘤在诊断时无法切除,需要有效的全身治疗.
- 人类表皮生长因子受体2 (HER2) 是5-30%的GEAs的关键驱动因素.
研究的目的:
- 在胃食道腺癌 (GEAs) 中审查HER2向策略.
- 总结HER2导向疗法的成功,挑战和未来前景.
- 讨论抗性和反应的机制,以指导新的治疗策略.
主要方法:
- 对GEA中HER2向剂的当前文献的综述.
- 分析临床试验数据和新兴生物标志物研究.
- 检查耐药机制及其对治疗的影响.
主要成果:
- 特拉斯图祖马布,潘布罗利祖马布和特拉斯图祖马布德鲁克斯提康可以改变治疗范式.
- 患者对 HER2 向疗法的反应有显著差异.
- 像HER2表达水平这样的生物标志物可以预测反应,而异质性和分子变化可以导致耐药性.
结论:
- 有效的全身治疗对于不可切除的GEA至关重要.
- 了解HER2表达和抵抗机制对于优化治疗至关重要.
- 需要对新的HER2向策略和组合进行进一步的研究,以改善结果.
更多相关视频
10:28Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
相关概念视频
Mitogens and the Cell Cycle
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment Resistant Cancers
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Barrett Esophagus-II: Clinical Manifestations and Management
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
